Drug intelligence / Profile preview

bacitracin + lidocaine + neomycin + polymyxin b

Development stage
Approved
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Topical
01

Overview

This is a **combination topical drug** containing **bacitracin**, **neomycin**, and **polymyxin B**—all antibiotics—with the addition of **lidocaine**, a local anesthetic[5][7][8]. It is used to **prevent and treat bacterial skin infections** associated with minor wounds, cuts, scrapes, and burns, while providing **pain relief** via the anesthetic effect of lidocaine[5][7][9]. - **Bacitracin** inhibits bacterial cell wall synthesis by interfering with dephosphorylation of lipid carrier molecules[5][7]. - **Neomycin** is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit[5][7]. - **Polymyxin B** disrupts bacterial cell membranes by interacting with phospholipids[5][7]. - **Lidocaine** blocks sodium channels, preventing nerve impulse transmission and producing localized numbness[5][7][8]. This combination offers broad-spectrum antibacterial coverage (Gram-positive and Gram-negative bacteria) and is applied topically in ointment form; it is available over-the-counter in various regions[5][7][8][9]. Primary indications are prevention and treatment of skin infection and pain relief in minor injuries.

Brand names
Lanabiotic Ointment
Other names
bacitracin+lidocaine+neomycin+polymyxin bneomycin/polymyxin B/bacitracin/lidocainetriple antibiotic ointment with lidocaine
02

Targets

C55-PP (Undecaprenyl pyrophosphate)NaV (Voltage-gated sodium channels)Bacterial Ribosome

Beyond the preview

Go deeper on bacitracin + lidocaine + neomycin + polymyxin b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacitracin + lidocaine + neomycin + polymyxin b.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call